Voyager Therapeutics (VYGR) has put investors through the wringer. Since going public in 2015, their chips have swung wildly, from a high-rolling $30 down to a "you've got to be kidding me" $2.50. Why? Well, their early bet on curing neurological diseases hit some snags. But, things seem to be turning around for them these
Global Market Comments April 4, 2024 Fiat Lux Featured Trade: (A NOTE ON OPTIONS CALLED AWAY), (FCX), (XOM), (OXY), (WPM), (TSLA)
Occasionally, I get a call from Concierge members asking what to do when their short position options are assigned or called away. The answer was very simple: fall down on your knees and thank your lucky stars. You have just made the maximum possible profit for your position instantly. We have the good fortune to
Mad Hedge Technology Letter April 3, 2024 Fiat Lux Featured Trade: (TESLA ON THE BACK FOOT) (TSLA)
Peak Tesla? It sure seems like it. I don’t want to jinx the company, but it is highly likely that it is passed its best. The data is looking increasingly gloomy and could set the stage for an even larger drop into irrelevance. In short, it’s definitely not looking too bright for the company that
“I definitely fall into the camp of thinking of AI as augmenting human capability and capacity.” – Said Microsoft CEO Satya Nadella
(ANALYSTS AND INVESTORS ARE STARTING TO PAY ATTENTION TO THE ENERGY SECTOR) April 3, 2024 Hello everyone. The month of April is upon us, and the market environment has turned a little cloudy. Economic data and heightened geopolitical risks appear to be fuelling the move higher in Oil prices. With the new month,
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.
Mad Hedge Biotech and Healthcare Letter April 2, 2024 Fiat Lux Featured Trade: (BREATHE EASY) (MRK), (JNJ)
It looks like Merck (MRK) just scored a major touchdown in the drug wars, which might make the looming Keytruda patent expiration sting a little less. Remember when Merck dropped $11.5 billion on Acceleron back in 2021 to get their hands on Winrevair (then known as Sotatercept)? That was a seriously gutsy move to soften